Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III purchased 13,700 shares of the business’s stock in a transaction that occurred on Tuesday, October 31st. The stock was purchased at an average price of $19.81 per share, for a total transaction of $271,397.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.10. The company had revenue of $13.34 million for the quarter, compared to analyst estimates of $8.15 million. Xencor had a negative return on equity of 13.79% and a negative net margin of 121.04%.

COPYRIGHT VIOLATION WARNING: “Xencor, Inc. (XNCR) Major Shareholder Buys $271,397.00 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/11/02/xencor-inc-xncr-major-shareholder-buys-271397-00-in-stock.html.

Institutional investors and hedge funds have recently modified their holdings of the business. Equitec Specialists LLC acquired a new position in Xencor in the second quarter valued at approximately $116,000. SG Americas Securities LLC lifted its stake in Xencor by 62.6% in the second quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 3,252 shares during the period. Legal & General Group Plc lifted its stake in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 385 shares during the period. Citadel Advisors LLC acquired a new position in Xencor in the second quarter valued at approximately $224,000. Finally, Airain ltd lifted its stake in Xencor by 49.9% in the second quarter. Airain ltd now owns 13,360 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 4,447 shares during the period. 76.81% of the stock is currently owned by hedge funds and other institutional investors.

XNCR has been the topic of a number of analyst reports. Canaccord Genuity reiterated a “buy” rating and issued a $36.00 price target on shares of Xencor in a research report on Tuesday, August 8th. ValuEngine upgraded shares of Xencor from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Finally, Zacks Investment Research downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Three investment analysts have rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. Xencor currently has a consensus rating of “Hold” and an average price target of $28.00.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.